Hesperidin RCT in MS

NCT07452562 | Recruiting

• 1 other identifier: NECTAR-MS
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.

Conditions

Multiple Sclerosis

Keywords

RCT; Hesperidin; Diet

Outcome Measures

Primary Outcomes (1)

• Fatigue

  Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS; Fisk et al., 1994), with the MFIS total score as the primary endpoint. MFIS subscale scores (physical, cognitive, psychosocial) and the Fatigue Severity Scale (FSS; Krupp et al., 1989) will be analysed as secondary outcomes to determine effects across different components of fatigue.

  Baseline and Week 12

Secondary Outcomes (2)

• Mood and Stress

  Baseline and Week 12

• Cognitive Function Battery

  Baseline and Week 12

Study Arms (2)

Hesperidin

ACTIVE COMPARATOR

Participants receiving Hesperidin capsules for 12 weeks.

Dietary Supplement: Hesperidin

Placebo Comparator

PLACEBO COMPARATOR

Participants receiving matching placebo capsules for 12 weeks.

Dietary Supplement: Placebo

Interventions

Hesperidin DIETARY_SUPPLEMENT

500 mg/day Hesperidin capsules for 12 weeks

Hesperidin

Placebo DIETARY_SUPPLEMENT

Matching maltodextrin capsules for 12 weeks.

Placebo Comparator

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of Multiple Sclerosis, Aged 18 years or older.

You may not qualify if:

• Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.

Sponsors & Collaborators

• Swansea University: lead
• BioActor B.V.: collaborator

Study Sites (1)

FHMLS, Nutrition Lab

Swansea, Wales, SA2 8PP, United Kingdom

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis

Interventions

Hesperidin

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Flavanones; Flavonoids; Chromones; Benzopyrans; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Glycosides; Carbohydrates

Study Officials

• Hayley A Young, PHD

  Swansea University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hayley Young, PhD

CONTACT

+44 (0) 1792 295908; h.a.young@swansea.ac.uk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: February 28, 2026
• First Posted: March 5, 2026
• Study Start: January 7, 2026
• Primary Completion (Estimated): January 18, 2027
• Study Completion (Estimated): January 18, 2027
• Last Updated: March 5, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)